If you have been reading about LC-MS and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-06-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
该分子是经过结构修饰的合成肽，通过脂肪酸侧链与白蛋白结合，从而延长循环时间。皮下给药后，药物逐步释放并分布至组织。降解主要依赖蛋白酶，肾脏清除占次要地位。人体半衰期以天为单位，但准确数值随检测方法和个体差异而变；组织分布与受体占有率仍是开放问题。
临床研究通常测量体重、腰围、空腹血糖、糖化血红蛋白和血脂，并记录不良事件。药代动力学评估关注浓度-时间曲线，药效动力学评估关注代谢标志物变化。体重下降由能量摄入减少、能量消耗变化和脂肪组织重塑共同造成，具体权重仍不明确。研究之间的终点定义和随访时长差异使横向比较复杂。
瑞他鲁肽同时激活GLP-1受体、GIP受体和胰高血糖素受体，这三者均属于B类G蛋白偶联受体。受体激活后主要经cAMP信号通路传递效应。GLP-1成分与食欲抑制和胃排空延缓相关，GIP成分影响脂肪组织与胰岛素分泌，胰高血糖素成分则促进肝糖输出和能量消耗。各受体贡献的相对比例在人体中尚未完全量化。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
As a peptide, the compound is generally supplied as a lyophilized powder and stored frozen to slow degradation. Recommended conditions usually sit at minus twenty degrees Celsius or colder, shielded from light and moisture. Solutions are less stable than the dry powder and are often prepared fresh before analysis. Repeated freeze-thaw cycles can drive aggregation, so splitting stock material into small aliquots reduces handling stress and preserves sample integrity.
Quality control of research material relies on several complementary checks. Purity testing confirms the absence of truncated or oxidized peptide species, while water content and counterion analysis show how much mass comes from salts rather than the peptide itself. Sequence verification through tandem mass spectrometry ensures the correct amino acid chain. Because unregulated suppliers vary widely, independent verification of identity and purity is often necessary before a sample enters experiments.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Solid material is generally held at -20 °C or colder, while reconstituted solutions are kept at 2-8 °C and used within a short window. Buffers that maintain a slightly acidic to neutral pH tend to improve short-term peptide stability. Repeated warming and cooling of stock solutions promotes aggregation and should be avoided. Container closures should remain intact, since adsorption to some plastics can reduce the amount of peptide in solution.
Identity and purity are established with reversed-phase high-performance liquid chromatography and mass spectrometry. Chromatographic profiles reveal related impurities, truncated sequences, and oxidation products, while mass measurement confirms the expected molecular mass. Purity values for research material are typically reported as a percentage by peak area. Reference standards help calibrate retention behavior across instruments. Independent laboratories emphasize method suitability because results depend heavily on column chemistry, gradient, and detection wavelength. Batch-to-batch comparison relies on the same validated method.
Investigational peptide material is commonly distributed as a lyophilized powder in sealed vials. The solid form appears as a white to off-white cake or powder and is hygroscopic once opened. Peptides of this size are sensitive to moisture, repeated freeze-thaw cycles, and prolonged exposure to ambient light. Handling practices therefore emphasize desiccation, minimal vial opening, and cold storage. Working aliquots are often prepared to avoid repeatedly warming the bulk container.
== Early life == Elizabeth Evans Hughes was born August 19, 1907, in the New York State Executive Mansion in Albany, New York, to Antoinette (Carter) and Charles Evans Hughes, who was Governor of New York at the time. Elizabeth developed diabetes in 1918 at age 11. At the time, the life expectancy of a Type 1 diabetic without treatment was usually no more than a few months. Since it was unable to metabolize sugars, the diabetic body would instead begin to burn fats. The dependence on fat would eventually lead to acidosis, followed by coma and death. The only known treatment was a low-carbohydrate low-calorie diet at a level that the patient could tolerate without showing sugar in the urine. If the diet was carefully observed, diabetics could expect to live for a couple of years before eventually succumbing to starvation, organ damage, or an infectious disease in their malnourished state. In spring 1919, Elizabeth Hughes was brought to Dr. Frederick Madison Allen at his special clinic, the Physiatric Institute in Morristown, New Jersey. Allen put her on a strict diet and continued to monitor her condition over the next three years while she lived at home with a private nurse. She was 4 feet 11.5 inches (1.511 m) and 75 pounds (34 kg) when she developed diabetes. Under diets that averaged 800 calories per day, her weight fell to 45 pounds (20 kg) by August 1922.
α-Melanocyte-stimulating hormone (α-MSH) is an endogenous peptide hormone and neuropeptide of the melanocortin family, with a tridecapeptide structure and the amino acid sequence Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2. It is the most important of the melanocyte-stimulating hormones (MSHs) (also known as melanotropins) in stimulating melanogenesis, a process that in mammals (including humans) is responsible for pigmentation primarily of the hair and skin. It also plays a role in feeding behavior, energy homeostasis, sexual activity, and protection against ischemia and reperfusion injury. α-MSH is a non-selective full agonist of the melanocortin receptors MC1 (Ki = 0.230 nM), MC3 (Ki = 31.5 nM), MC4 (Ki = 900 nM), and MC5 (Ki = 7160 nM), but not MC2 (which is exclusive for adrenocorticotropic hormone (ACTH)). Activation of the MC1 receptor is responsible for its effect on pigmentation, whereas its regulation of appetite, metabolism, and sexual behavior is mediated through both the MC3 and MC4 receptors. It is generated as a proteolyic cleavage product from ACTH (1-13), which is in turn a cleavage product of proopiomelanocortin (POMC). A few synthetic analogues of α-MSH have been investigated as medicinal drugs due to their photoprotective effects against ultraviolet (UV) radiation from the sun. They include afamelanotide (melanotan) and melanotan II, the former of which has been approved as a treatment to reduce photosensitivity in erythropoietic protoporphyria in the United States.
where λz is the slope of the terminal phase of the time–concentration curve for the substance on a semilogarithmic scale. Half-life is determined by clearance (CL) and volume of distribution (VD) and the relationship is described by the following equation:
Schnölzer M, Kent SB. 1992, "Constructing proteins by dovetailing unprotected synthetic peptides: backbone-engineered HIV protease." Science. 256:221-5 Dawson PE, Muir TW, Clark-Lewis I, Kent SB. 1994, "Synthesis of proteins by native chemical ligation." Science. 266:776-9. Muir TW. 2003, "Semisynthesis of proteins by expressed protein ligation." Annu Rev Biochem. 72:249-89. Nilsson BL, Soellner MB, Raines RT. 2005, "Chemical Synthesis of Proteins." Annu. Rev. Biophys. Biomol. Struct. 34:91-118 Bang D, Pentelute BL, Kent SB. 2006, "Kinetically controlled ligation for the convergent chemical synthesis of proteins." Angew Chem Int Ed Engl. 45:3985-8. Kent SB. 2009, "Total chemical synthesis of proteins." Chem.Soc.Rev. 38, 338–351. doi:10.1039/b700141j. Zhang Y, Xu C, Kam HY, Lee CL, Li X. 2013, "Protein chemical synthesis by serine/threonine ligation." Proc. Natl. Acad. Sci. USA. 17:6657-6662
Sources: en.wikipedia.org
== Current popular procedures == Since 2000, more products and techniques have been developed to make lip augmentation more effective and patient friendly. The relative ease of many injections is due to surgeons using tiny 30 and 31 gauge (about as thick as a dozen human hairs) needles that are used to inject the very sensitive lips. Nonetheless, topical anesthesias are often used for lip augmentation procedures. Some of these new techniques and substances include:
== Side effects == Side effects of azapirones may include dizziness, headaches, restlessness, nausea, and diarrhea. Azapirones have more tolerable adverse effects than many other available anxiolytics, such as benzodiazepines or SSRIs. Unlike benzodiazepines, azapirones lack abuse potential and are not addictive, do not cause cognitive/memory impairment or sedation, and do not appear to induce appreciable tolerance or physical dependence. However, azapirones are considered less effective with slow onset in controlling symptoms.
=== Metabolism === Meloxicam is extensively metabolized in the liver by the enzymes CYP2C9 and CYP3A4 (minor) into four inactive metabolites. Peroxidase activity is thought to be responsible for the other two remaining metabolites.
a Total body clearance/F = Dose/AUC b Steady state volume of distribution/F = Dose•AUMC/AUC2 c Volume of distribution (area)/F = Vdβ = (T1/2)(CL/F)/0.693 As mentioned above, Difloxacin is not FDA-approved for use in cats. This is because the major route of metabolism is through glucuronidation, an enzymatic pathway that cats lack. Therefore, administration to cats would likely result in toxicity. Difloxacin is stored at room temperature in a cool, dry place.
== Manufacturing == Although pseudoephedrine occurs naturally as an alkaloid in certain plant species (for example, as a constituent of extracts from the Ephedra species, also known as ma huang, in which it occurs together with other isomers of ephedrine), the majority of pseudoephedrine produced for commercial use is derived from yeast fermentation of dextrose in the presence of benzaldehyde. In this process, specialized strains of yeast (typically a variety of Candida utilis or Saccharomyces cerevisiae) are added to large vats containing water, dextrose and the enzyme pyruvate decarboxylase (such as found in beets and other plants). After the yeast has begun fermenting the dextrose, the benzaldehyde is added to the vats, and in this environment, the yeast converts the ingredients to the precursor l-phenylacetylcarbinol (L-PAC). L-PAC is then chemically converted to pseudoephedrine via reductive amination. The bulk of pseudoephedrine is produced by commercial pharmaceutical manufacturers in India and China, where economic and industrial conditions favor its mass production for export.
Sources: en.wikipedia.org
==== 20th century ==== In response to concerns about the risks of occupational polonium exposure, quantities of 210Po were administered to five human volunteers at the University of Rochester from 1944 to 1947, in order to study its biological behaviour. These studies were funded by the Manhattan Project and the AEC. Four men and a woman participated, all suffering from terminal cancers, and ranged in age from their early thirties to early forties; all were chosen because experimenters wanted subjects who had not been exposed to polonium either through work or accident. 210Po was injected into four hospitalised patients, and orally given to a fifth. None of the administered doses (all ranging from 0.17 to 0.30 μCi kg−1) approached fatal quantities. The first documented death directly resulting from polonium poisoning occurred in the Soviet Union, on 10 July 1954. An unidentified 41-year-old man presented for medical treatment on 29 June, with severe vomiting and fever; the previous day, he had been working for five hours in an area in which, unknown to him, a capsule containing 210Po had depressurised and begun to disperse in aerosol form. Over this period, his total intake of airborne 210Po was estimated at 0.11 GBq (almost 25 times the estimated LD50 by inhalation of 4.5 MBq). Despite treatment, his condition continued to worsen and he died 13 days after the exposure event. From 1955 to 1957 the Windscale Piles had been releasing polonium-210.
=== Education and early law career === Duterte went to Laboon Elementary School in Maasin for a year. He spent his remaining elementary days at Santa Ana Elementary School in Davao City, where he completed his primary education in 1956. He finished his secondary education in the High School Department of Holy Cross College of Digos (now Cor Jesu College) in Digos, Davao province, after being expelled twice from previous schools, including one in the Ateneo de Davao University (AdDU) High School due to misconduct. He graduated in 1968 with a Bachelor of Arts degree in political science at the Lyceum of the Philippines in Manila. Duterte obtained a law degree from San Beda College of Law in 1972, passing the bar exam in the same year. He worked as a professor in the national police academy, and was a member of an organization called Nationalist Alliance for Justice, Freedom and Democracy. He later served as the OIC vice mayor of Davao City, assisting evacuees from Davao City remote areas and working for the release of soldiers captured by the New Peoples Army (NPA). Eventually, he became a special counsel at the City Prosecution Office in Davao City from 1977 to 1979, fourth assistant city prosecutor from 1979 to 1981, third assistant city prosecutor from 1981 to 1983, and second assistant city prosecutor from 1983 to 1986.
== The Real Housewives of Cheshire == In January 2015, the British reality TV series The Real Housewives of Cheshire debuted with Pickston, Leanne Brown, Magali Gorré, Tanya Bardsley, Lauren Simon and Dawn Ward. A British adaptation of the long-running American franchise The Real Housewives, the series follows the lives of a group of wealthy women in Cheshire. Pickston left the show at the end of fifth series, in 2017, after appearing in 55 episodes and three reunions. Pickston returned to the show in a guest capacity in the sixteenth series (2023) and featured in a recurring capacity for the seventeenth series (2024). The eighteenth series (2025) celebrated ten years of the show, which Pickston appeared in. Pickston returned to the show in a full-time role from the nineteenth series, in 2026. Pickston won the Best Female Personality Award at the Sixth Annual National Reality TV Awards.
== Stability == Avobenzone is sensitive to the properties of the solvent, being relatively stable in polar protic solvents and unstable in nonpolar environments. Also, when it is irradiated with UVA light, it generates a triplet excited state in the keto form which can either cause the avobenzone to degrade or it can transfer energy to biological targets and cause deleterious effects. Avobenzone has been shown to degrade significantly in light, resulting in less protection over time. The UV-A light in a day of sunlight in a temperate climate is sufficient to break down most of the compound. Data presented to the Food and Drug Administration by the Cosmetic, Toiletry and Fragrance Association indicates a −36% change in avobenzone's UV absorbance following one hour of exposure to sunlight. For this reason, in sunscreen products, avobenzone is always formulated together with a photostabilizer, such as octocrylene. Other photostabilizers include:
== Further reading == Hsu, Jeremy (May 23, 2025). "Trump's Golden Dome defence project could spur a space arms race". New Scientist. Retrieved May 27, 2025. Hennigan, W.J. (May 20, 2025). "The Reality of Trump's Golden Dome". The New York Times. Retrieved May 27, 2025. Mitchell, Ellen (May 4, 2025). "5 things to know as Trump rolls out Golden Dome missile defense shield". The Hill. Retrieved May 6, 2025. Maidenberg, Micah; Fitzgerald, Drew (May 4, 2025). "Everyone Wants a Piece of Trump's 'Golden Dome' Defense Plan". The Wall Street Journal. Retrieved May 6, 2025. Scoles, Sarah, "Dome's Long Shot: Golden Dome calls for missile interceptors in orbit to defend the U.S. Companies are already lining up to build a system that doesn't yet exist", Scientific American, vol. 335, no. 2 (September 2026), pp. 80–81. "In [the view of Todd] Harrison [a senior fellow at the American Enterprise Institute], it'll be a good long while before anyone knows how many thousands of interceptors will be in orbit or how they'll mesh with the rest of the dome. By the time the architecture is even set, he says, Golden Dome will probably have changed forms, been canceled and been resurrected with a different name." (p. 81.)
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
意味着单个分子可同时结合三种代谢受体，而不是只作用于一种。其目的是整合食欲、胰岛素和能量消耗通路，但人体中的协同程度仍在研究。